Showing Results for
- Academic Journals (3,042)
- Images (1)
Search Results
- 3,042
Academic Journals
- 3,042
- Search Terms:
- 1From: Oncology. (Vol. 27, Issue 5) Peer-ReviewedOncology Journal "Cancer, above all other diseases, has countless secondary causes. But, even for cancer, there is only one prime cause. Summarized in a few words, the prime cause of cancer is the replacement of the...
- 2From: Oncology. (Vol. 34, Issue 11) Peer-ReviewedBACKGROUND. Physicians look to various electronic resources to aid in management of patient treatment. Although national guidelines encourage clinical trial participation for patients with cancer, it is unclear if...
- 3From: Oncology. (Vol. 34, Issue 7) Peer-ReviewedThe coronavirus disease 2019 (COVID-19) shows no signs of slowing down or burning out, with cases in the United States reaching daily highs in several locations. Although infectious disease specialists and...
- 4From: Oncology. (Vol. 34, Issue 1) Peer-ReviewedLEARNING OBJECTIVES Upon successful completion of this activity, you should be better prepared to: * Explain the rationale for the use of PI3K Inhibitors to treat patients with breast cancer. * Outline the most...
- 5From: Oncology. (Vol. 34, Issue 10) Peer-ReviewedWorldwide incidence and mortality due to the coronavirus disease 2019 (COVID-19) pandemic is greatest in the United States, with the initial epicenter in New York. In Nassau County, New York, where we practice, our...
- 6From: Oncology. (Vol. 35, Issue 5) Peer-ReviewedBACKGROUND: Pancreatic adenocarcinoma (PDAC) is relatively rare but highly aggressive, with most patients diagnosed once they have metastatic or locally invasive disease. Molecular profiling is being explored as a tool...
- 7From: Oncology. (Vol. 34, Issue 11) Peer-ReviewedAdolescents and young adults [AYAs] with cancer constitute approximately 70,000 patients diagnosed each year. Survival rates for AYAs with cancer have increased steadily in recent decades due to improvements in...
- 8From: Oncology. (Vol. 33, Issue 10) Peer-ReviewedThis paper offers a clear review of personality disorders for the oncologist, with helpful suggestions for their management. Clinicians may also benefit from considering a few additional points: First, just as...
- 9From: Oncology. (Vol. 34, Issue 6) Peer-ReviewedThere are numerous options when it comes to reporting visits that are not the traditional face-to-face office visit. This varies somewhat by payer, of course. Medicare has temporarily relaxed some of the geographic and...
- 10From: Oncology. (Vol. 34, Issue 12) Peer-ReviewedResearchers have found an added benefit in terms of mortality due to the longer overall survival with the drug enzalutamide (Xtandi) to treat adult patients with high-risk nonmetastatic castration-resistant prostate...
- 11From: Oncology. (Vol. 34, Issue 8) Peer-ReviewedApproximately 1.7 million people are diagnosed with cancer yearly in the United States and of those, almost 25% are aged less than 45 years. (1) Most data estimate that annually, 54,000 Americans treated for cancer will...
- 12From: Oncology. (Vol. 34, Issue 2) Peer-ReviewedThe FDA approved pembrolizumab (Keytruda) for the treatment of patients with Bacillus Calmette-Guerin (BCG)-unresponsive, high-risk, non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without...
- 13From: Oncology. (Vol. 35, Issue 2) Peer-ReviewedSymptomatic spinal metastasis is a frequent complication of cancer that had been treated, until relatively recently, with primitive techniques to modest radiation dose levels, with a baseline assumption of limited...
- 14From: Oncology. (Vol. 35, Issue 11) Peer-ReviewedProduct Profile Drug name: Tepotinib (Tepmetko) Date of approval: February 3, 2021 Initial indication: Accelerated approval for the treatment of adult patients with metastatic non-small cell lung cancer harboring...
- 15From: Oncology. (Vol. 35, Issue 10) Peer-ReviewedQ: What are some of the biggest concerns with umbralisib's toxicity profile? Have any new safety concerns emerged in the real-world treatment setting? We haven't seen anything that stood out beyond what we were already...
- 16From: Oncology. (Vol. 36, Issue 3) Peer-ReviewedProstate-specific antigen (PSA) values above 100 ng/mL often suggest metastatic prostate cancer. We present the case of a patient with a PSA of 110 ng/mL, 4 negative prostate biopsies, and 4 negative prostate MRIs. After...
- 17From: Oncology. (Vol. 36, Issue 6) Peer-ReviewedLEARNING OBJECTIVES Upon successful completion of this activity, you should be better prepared to: * Review the role of biomarkers in diagnosing and monitoring neuroendocrine neoplasms (NENs) * Discuss clinically...
- 18From: Oncology. (Vol. 24, Issue 3) Peer-ReviewedAnemia is a widely prevalent complication among cancer patients. At the time of diagnosis, 30% to 40% of patients with non-Hodgkin lymphoma or Hodgkin lymphoma and up to 70% of patients with multiple myeloma are anemic;...
- 19From: Oncology. (Vol. 30, Issue 12) Peer-ReviewedThe management of mantle cell lymphoma has evolved dramatically since 1994, when the Revised European-American Lymphoma Classification recognized it as a separate disease entity. This was based not only on the distinct...
- 20From: Oncology. (Vol. 36, Issue 1) Peer-ReviewedDiffuse large B-cell lymphoma [DLBCL], the most common subtype of non-Hodgkin lymphoma, is an aggressive and biologically heterogeneous disease. Risk stratification and treatment algorithms vary based on stage of disease...